CL2022001636A1 - Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina - Google Patents

Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina

Info

Publication number
CL2022001636A1
CL2022001636A1 CL2022001636A CL2022001636A CL2022001636A1 CL 2022001636 A1 CL2022001636 A1 CL 2022001636A1 CL 2022001636 A CL2022001636 A CL 2022001636A CL 2022001636 A CL2022001636 A CL 2022001636A CL 2022001636 A1 CL2022001636 A1 CL 2022001636A1
Authority
CL
Chile
Prior art keywords
long
injectable formulations
acting injectable
ketamine pamoate
pamoate salts
Prior art date
Application number
CL2022001636A
Other languages
English (en)
Inventor
Tong-Ho Lin Tong-Ho Lin
Wen Yung-Shun
Chen Chia-Hsien
Liu Ying-Ting
Hou Rui-Zhi
Wu Zhi-Rong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022001636A1 publication Critical patent/CL2022001636A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas de liberación sostenida que incluyen una sal de pamoato de ketamina y un portador farmacéuticamente aceptable de la misma. Las composiciones incluyen suspensión acuosa, solución y sistema de administración de matriz, que pueden proporcionar una liberación sostenida para anestesia, analgesia o tratamiento del sistema nervioso central y enfermedades antiinflamatorias.
CL2022001636A 2019-12-20 2022-06-16 Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina CL2022001636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962951061P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
CL2022001636A1 true CL2022001636A1 (es) 2023-01-27

Family

ID=76478186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001636A CL2022001636A1 (es) 2019-12-20 2022-06-16 Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina

Country Status (17)

Country Link
US (1) US20240099994A1 (es)
EP (1) EP4076410A4 (es)
JP (1) JP2023505963A (es)
KR (1) KR20220118427A (es)
CN (1) CN114340603B (es)
AR (1) AR120816A1 (es)
AU (1) AU2020410549A1 (es)
BR (1) BR112022012255A2 (es)
CA (1) CA3152593A1 (es)
CL (1) CL2022001636A1 (es)
CO (1) CO2022003543A2 (es)
IL (1) IL294089A (es)
MX (1) MX2022006596A (es)
PE (1) PE20231942A1 (es)
TW (1) TW202135782A (es)
WO (1) WO2021121366A1 (es)
ZA (1) ZA202203789B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2023178039A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
CN105073103A (zh) * 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
IL315066A (en) * 2016-10-27 2024-10-01 Univ Chiba Nat Univ Corp Pharmaceutical applications of (S)-norketamine and its salts
CN110325179A (zh) * 2016-12-26 2019-10-11 塞尔利克斯生物私人有限公司 用于治疗慢性疼痛的组合物和方法
CA3077645A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. A solid extended-release pharmaceutical formulations comprising ketamine or norketamine
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019172920A1 (en) * 2018-03-09 2019-09-12 Rk Pharmaceuticals, Llc Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
WO2019186357A1 (en) * 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP7451538B2 (ja) * 2019-01-11 2024-03-18 ▲ユ▼展新藥生技股分有限公司 ケタミンパモエート及びその使用

Also Published As

Publication number Publication date
AU2020410549A1 (en) 2022-04-14
MX2022006596A (es) 2022-07-05
EP4076410A4 (en) 2024-02-07
WO2021121366A1 (en) 2021-06-24
PE20231942A1 (es) 2023-12-05
KR20220118427A (ko) 2022-08-25
BR112022012255A2 (pt) 2022-08-30
CA3152593A1 (en) 2021-06-24
EP4076410A1 (en) 2022-10-26
CN114340603B (zh) 2024-06-07
IL294089A (en) 2022-08-01
US20240099994A1 (en) 2024-03-28
ZA202203789B (en) 2024-09-25
AR120816A1 (es) 2022-03-23
TW202135782A (zh) 2021-10-01
CO2022003543A2 (es) 2022-04-19
JP2023505963A (ja) 2023-02-14
CN114340603A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
CL2022001636A1 (es) Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY38174A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros compuestos relacionados, como inhibidores del complemento
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
BR112015010980A2 (pt) composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
AR064727A1 (es) Derivados de [1,8]naftiridin-2-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos asociados al snc.
UA120764U (uk) Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл"
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CU20160170A7 (es) Derivados de carboxamida